- Home
- LXFR vs RCKT Comparison
LXFR vs RCKT Comparison
Compare LXFR & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXFR | RCKT |
|---|---|---|
| Founded | 1898 | 1999 |
| Country | United States | United States |
| Employees | 1400 | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.5M | 394.2M |
| IPO Year | 2002 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LXFR | RCKT |
|---|---|---|
| Price | $17.15 | $3.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $29.73 |
| AVG Volume (30 Days) | 362.7K | ★ 1.4M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | 0.31 | ★ 0.66 |
| Revenue | ★ $384,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.01 | $64.28 |
| P/E Ratio | $132.08 | ★ $5.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.26 | $2.53 |
| 52 Week High | $19.45 | $5.45 |
Technical Indicators
Market Signals| Indicator | LXFR | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 52.30 | 56.60 |
| Support Level | $16.68 | $3.32 |
| Resistance Level | $17.40 | $4.04 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 61.54 | 75.93 |
Price Performance
Historical ComparisonAbout LXFR Luxfer Holdings PLC
Luxfer Holdings PLC is engaged in materials engineering and the manufacture of materials, components, and gas containment products. The company has two reportable segments: Elektron and Gas Cylinders. The Elektron segment produces specialty materials based on magnesium and zirconium for applications in aerospace, defense, automotive, and industrial markets. The Gas Cylinders segment manufactures high-pressure gas containment products using aluminum alloys and carbon composite technologies for use in healthcare, emergency response, aerospace, and alternative fuel transportation markets.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.